The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions

被引:165
作者
Mitsiades, Constantine S.
Mitsiades, Nicholas S.
Munshi, Nikhil C.
Richardson, Paul G.
Anderson, Kenneth C.
机构
[1] Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol,Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
关键词
multiple myeloma;
D O I
10.1016/j.ejca.2005.12.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The close relationship between the biological behaviour of malignant cells and the local microenvironment where they reside is a feature of diverse neoplasias. Multiple myeloma (MM) is considered a main disease model for the study of such interactions and the mechanisms that can lead to bone-related clinical complications, as well as the role of these interactions in attenuating the activity of conventional anti-MM therapeutics, such as dexamethasone and cytotoxic chemotherapeutics. This review focuses on recent progress in the study of interactions of MM cells with their local microenvironment. Major emphasis is placed on how bone marrow stromal cells (BMSCs) and other normal constituents of the bone marrow milieu promote, through cell adhesion- and cytokine-mediated mechanisms, the ability of MM cells to resist conventional anti-MM therapies. The review also addresses ongoing research into these mechanisms, which has already provided several new molecular targets and corresponding therapeutic strategies, such as the proteasome inhibitor bortezomib and thalidomide derivatives (e.g. lenalidomide), for the management of myeloma. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1564 / 1573
页数:10
相关论文
共 114 条
[1]   Structure and function of the type 1 insulin-like growth factor receptor [J].
Adams, TE ;
Epa, VC ;
Garrett, TPJ ;
Ward, CW .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (07) :1050-1093
[2]   Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma [J].
Alsina, M ;
Fonseca, R ;
Wilson, EF ;
Belle, AN ;
Gerbino, E ;
Price-Troska, T ;
Overton, RM ;
Ahmann, G ;
Bruzek, LM ;
Adjei, AA ;
Kaufmann, SH ;
Wright, JJ ;
Sullivan, D ;
Djulbegovic, B ;
Cantor, AB ;
Greipp, PR ;
Dalton, WS ;
Sebti, SM .
BLOOD, 2004, 103 (09) :3271-3277
[3]   In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates [J].
Aparicio, A ;
Gardner, A ;
Tu, Y ;
Savage, A ;
Berenson, J ;
Lichtenstein, A .
LEUKEMIA, 1998, 12 (02) :220-229
[4]   BLOCKADE OF THE TYPE-I SOMATOMEDIN RECEPTOR INHIBITS GROWTH OF HUMAN-BREAST CANCER-CELLS IN ATHYMIC MICE [J].
ARTEAGA, CL ;
KITTEN, LJ ;
CORONADO, EB ;
JACOBS, S ;
KULL, FC ;
ALLRED, DC ;
OSBORNE, CK .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (05) :1418-1423
[5]  
ARTEAGA CL, 1989, CANCER RES, V49, P6237
[6]   Aetiology of bone disease and the role of bisphosphonates in multiple myeloma [J].
Ashcroft, AJ ;
Davies, FE ;
Morgan, GJ .
LANCET ONCOLOGY, 2003, 4 (05) :284-292
[7]   THE CRITICAL ROLE OF INTERLEUKIN-6, INTERLEUKIN-1B AND MACROPHAGE COLONY-STIMULATING FACTOR IN THE PATHOGENESIS OF BONE-LESIONS IN MULTIPLE-MYELOMA [J].
BATAILLE, R ;
CHAPPARD, D ;
KLEIN, B .
INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1992, 21 (04) :283-287
[8]   BIOLOGIC EFFECTS OF ANTI-INTERLEUKIN-6 MURINE MONOCLONAL-ANTIBODY IN ADVANCED MULTIPLE-MYELOMA [J].
BATAILLE, R ;
BARLOGIE, B ;
LU, ZY ;
ROSSI, JF ;
LAVABREBERTRAND, T ;
BECK, T ;
WIJDENES, J ;
BROCHIER, J ;
KLEIN, B .
BLOOD, 1995, 86 (02) :685-691
[9]   MECHANISMS OF BONE DESTRUCTION IN MULTIPLE-MYELOMA - THE IMPORTANCE OF AN UNBALANCED PROCESS IN DETERMINING THE SEVERITY OF LYTIC BONE-DISEASE [J].
BATAILLE, R ;
CHAPPARD, D ;
MARCELLI, C ;
DESSAUW, P ;
SANY, J ;
BALDET, P ;
ALEXANDRE, C .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (12) :1909-1914
[10]   TYROSINE PHOSPHORYLATION OF JAK-TYK KINASES IN MALIGNANT PLASMA-CELL LINES GROWTH-STIMULATED BY INTERLEUKIN-6 AND INTERLEUKIN-11 [J].
BERGER, LC ;
HAWLEY, TS ;
LUST, JA ;
GOLDMAN, SJ ;
HAWLEY, RG .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 202 (01) :596-605